In vivo analysis of adenovirus-specific cytotoxic T lymphocyte response in mice deficient in CD28, Fas ligand, and perforin

Human Gene Therapy

Volumn 17, Issue 6, 2006, Pages 669-682

  Chen, Jian ^a   Hsu, Hui Chen ^a   Zajac, Allan J ^b   Wu, Qi ^a   Yang, Pingar ^a   Xu, Xin ^a   McPherson, Sylvia A ^c   Li, Jun ^d   Curiel, David T ^a,d   Mountz, John D ^a,e,f  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e BIRMINGHAM VA MEDICAL CENTER   (United States)

^f The University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; DRUG CARRIER; FAS LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PERFORIN; TUMOR NECROSIS FACTOR ALPHA; VACCINE;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; GENE THERAPY; MOUSE; NONHUMAN; TARGET CELL; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD28; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FAS LIGAND PROTEIN; FEMALE; GENETIC VECTORS; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PORE FORMING CYTOTOXIC PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR-ALPHA; TUMOR NECROSIS FACTORS;

ADENOVIRIDAE;

EID: 33745669424     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.669     Document Type: Article

References (61)

1. + effector T cell responses. J. Immunol. 164, 3689-3697.
2. AUNG, S., RUTIGLIANO, J.A., and GRAHAM, B.S. (2001). Alternative mechanisms of respiratory syncytial virus clearance in perforin knockout mice lead to enhanced disease. J. Virol. 75, 9918-9924.
3. + T cell response to Listeria monocytogenes in the absence of perforin and IFN-γ. J. Immunol. 164, 6444-6452.
4. BOOKER, J.K., REAP, E.A., and COHEN, P.L. (1998). Expression and function of Fas on cells damaged by γ-irradiation in B6 and B6/lpr mice. J. Immunol. 161, 4536-4541.
5. CALDWELL, S.A., RYAN, M.H., McDUFFIE, E., and ABRAMS, S.I. (2003). The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases. J. Immunol. 171, 2402-2412.
6. + T cells in vitro. J. Immunol. 163, 1298-1305.
7. CHEN, J., ZAJAC, A.J., McPHERSON, S.A., HSU, H.C., YANG, P., WU, Q., XU, X., WANG, X., FUJIHASHI, K., CURIEL, D.T., and MOUNTZ, J.D. (2005). Primary adenovirus-specific cytotoxic T lymphocyte response occurs after viral clearance and liver enzyme elevation. Gene Ther. 12, 1079-1088.
8. CHIRMULE, N., MOFFETT, J., DHAGAT, P., TAZELAAR, J., and WILSON, J.M. (1999a). Adenoviral vector-mediated gene therapy in the mouse lung: No role of Fas-Fas ligand interactions for elimination of transgene expression in bronchioepithelial cells. Hum. Gene Ther. 10, 2839-2846.
9. CHIRMULE, N., MOSCIONI, A.D., QIAN, Y., QIAN, R., CHEN, Y., and WILSON, J.M. (1999b). Fas-Fas ligand interactions play a major role in effector functions of cytotoxic T lymphocytes after adenovirus vector-mediated gene transfer. Hum. Gene Ther. 10, 259-269.
10. COLES, R.M., MUELLER, S.N., HEATH, W.R., CARBONE, F.R., and BROOKS, A.G. (2002). Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1. J. Immunol. 168, 834-838.
11. DITTEL, B.N., MERCHANT, R.M., and JANEWAY, C.A., Jr. (1999). Evidence for Fas-dependent and Fas-independent mechanisms in the pathogenesis of experimental autoimmune encephalomyelitis. J. Immunol. 162, 6392-6400.
12. ELKON, K.B., LIU, C.C., GALL, J.G., TREVEJO, J., MARINO, M.W., ABRAHAMSEN, K.A., SONG, X., ZHOU, J.L., OLD, L.J., CRYSTAL, R.G., and FALCK-PEDERSEN, E. (1997). Tumor necrosis factor a plays a central role in immune-mediated clearance of adenoviral vectors. Proc. Natl. Acad. Sci. U.S.A. 94, 9814-9819.
13. EVERETT, R.S., HODGES, B.L., DING, E.Y., XU, F., SERRA, D., and AMALFITANO, A. (2003). Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of El, E2b-deleted adenoviral vectors. Hum. Gene Ther. 14, 1715-1726.
14. FULLER, M.J., and ZAJAC, A.J. (2003). Ablation of CD8 and CD4 T cell responses by high viral loads. J. Immunol. 170, 477-486.
15. + T cells independently of the CD28/B7 and LFA-1/ICAM-1 costimulatory interactions. J. Immunol. 160, 3180-3187.
16. + cytotoxic T lymphocytes in the absence of exogenous help. J. Exp. Med. 177, 1791-1796.
17. + T cell effector mechanisms in resistance to infection. Annu. Rev. Immunol. 18, 275-308.
18. JIANG, Z., FEINGOLD, E., KOCHANEK, S., and CLEMENS, P.R. (2002). Systemic delivery of a high-capacity adenoviral vector expressing mouse CTLA4Ig improves skeletal muscle gene therapy. Mol. Ther. 6, 369-376.
19. JOGLER, C., HOFFMANN, D., THEEGARTEN, D., GRUNWALD, T., UBERLA, K., and WILDNER, O. (2006). Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species. J. Virol. 80, 3549-3558.
20. JOOSS, K., TURKA, L.A., and WILSON, J.M. (1998). Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Ther. 5, 309-319.
21. KAFRI, T., MORGAN, D., KRAHL, T., SARVETNICK, N., SHERMAN, L., and VERMA, I. (1998). Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: Implications for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 95, 11377-11382.
22. KAFROUNI, M.I., BROWN, G.R., and THIELE, D.L. (2001). Virally infected hepatocytes are resistant to perforin-dependent CTL effector mechanisms. J. Immunol. 167, 1566-1574.
23. KAFROUNI, M.I., BROWN, G.R., andTHIELE, D.L. (2003). The role of TNF-TNFR2 interactions in generation of CTL responses and clearance of hepatic adenovirus infection. J. Leukoc. Biol. 74, 564-571.
24. KAGI, D., LEDERMANN, B., BURKI, K., SEILER, P., ODERMATT, B., OLSEN, K.J., PODACK, E.R., ZINKERNAGEL, R.M., and HENGARTNER, H. (1994). Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369, 31-37.
25. KAST, W.M., OFFRINGA, R., PETERS, P.J., VOORDOUW, A.C., MELOEN, R.H., VAN DER EB, A.J., and MELIEF, C.J. (1989). Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell 59, 603-614.
26. KAY, M.A., HOLTERMAN, A.X., MEUSE, L., GOWN, A., OCHS, H.D., LINSLEY, P.S., and WILSON, C.B. (1995). Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat. Genet. 11, 191-197.
27. KOPF, M., COYLE, A.J., SCHMITZ, N., BARNER, M., OXENIUS, A., GALLIMORE, A., GUTIERREZ-RAMOS, J.C., and BACHMANN, M.F. (2000). Inducible costimulator protein (ICOS) controls T helper cell subset polarization after virus and parasite infection. J. Exp. Med. 192, 53-61.
28. KUNDIG, T.M., SHAHINIAN, A., KAWAI, K., MITTRUCKER, H.W., SEBZDA, E., BACHMANN, M.F., MAK, T.W., and OHASHI, P.S. (1996). Duration of TCR stimulation determines costimulatory requirement of T cells. Immunity 5, 41-52.
29. LIU, Y., WENGER, R.H., ZHAO, M., and NIELSEN, P.J. (1997). Distinct costimulatory molecules are required for the induction of effector and memory cytotoxic T lymphocytes. J. Exp. Med. 185, 251-262.
30. LUSKY, M., CHRIST, M., RITTNER, K., DIETERLE, A., DREYER, D., MOUROT, B., SCHULTZ, H., STOECKEL, F., PAVIRANI, A., and MEHTALI, M. (1998). In vitro and in vivo biology of recombinant adenovirus vectors with El, E1/E2A, or E1/E4 deleted. J. Virol. 72, 2022-2032.
31. + cytotoxic T-cell responses during chronic viral infection. J. Virol. 68, 8056-8063.
32. + T lymphocytes during infection with Listeria monocytogenes. J. Immunol. 167, 5620-5627.
33. MOLINIER-FRENKEL, V., GAHERY-SEGARD, H., MEHTALI, M., LE BOULAIRE, C., RIBAULT, S., BOULANGER, P., TURSZ, T., GUILLET, J.G., and FARACE, F. (2000). Immune response to recombinant adenovirus in humans: Capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes. J. Virol. 74, 7678-7682.
34. PARRA, B., LIN, M.T., STOHLMAN, S.A., BERGMANN, C.C., ATKINSON, R., and HINTON, D.R. (2000). Contributions of Fas-Fas ligand interactions to the pathogenesis of mouse hepatitis virus in the central nervous system. J. Virol. 74, 2447-2450.
35. ROTH, E., and PIRCHER, H. (2004). IFN-γ promotes Fas ligand- and perforin-mediated liver cell destruction by cytotoxic CD8 T cells. J. Immunol. 172, 1588-1594.
36. RUSSELL, J.H., and LEY, T.J. (2002). Lymphocyte-mediated cytotoxicity. Annu. Rev. Immunol. 20, 323-370.
37. SABELKO-DOWNES, K.A., CROSS, A.H., and RUSSELL, J.H. (1999). Dual role for Fas ligand in the initiation of and recovery from experimental allergic encephalomyelitis. J. Exp. Med. 189, 1195-1205.
38. SCHOWALTER, D.B., MEUSE, L., WILSON, C.B., LINSLEY, P.S., and KAY, M.A. (1997). Constitutive expression of murine CTLA4Ig from a recombinant adenovirus vector results in prolonged transgene expression. Gene Ther. 4, 853-860.
39. SHAHINIAN, A., PFEFFER, K., LEE, K.P., KUNDIG, T.M., KISHIHARA, K., WAKEHAM, A., KAWAI, K., OHASHI, P.S., THOMPSON, C.B., and MAK, T.W. (1993). Differential T cell costimulatory requirements in CD28-deficient mice. Science 261, 609-612.
40. SHIVER, J.W., FU, T.M., CHEN, L., CASIMIRO, D.R., DAVIES, M.E., EVANS, R.K., ZHANG, Z.Q., SIMON, A.J., TRIGONA, W.L., DUBEY, S.A., HUANG, L., HARRIS, V.A., LONG, R.S., LIANG, X., HANDT, L., SCHLEIF, W.A., ZHU, L., FREED, D.C., PERSAUD, N.V., GUAN, L., PUNT, K.S., TANG, A., CHEN, M., WILSON, K.A., COLLINS, K.B., HEIDECKER, G.J., FERNANDEZ, V.R., PERRY, H.C., JOYCE, J.G., GRIMM, K.M., COOK, J.C., KELLER, P.M., KRESOCK, D.S., MACH, H., TROUTMAN, R.D., ISOPI, L.A., WILLIAMS, D.M., XU, Z., BOHANNON, K.E., VOLKIN, D.B., MONTEFIORI, D.C., MIURA, A., KRIVULKA, G.R., LIFTON, M.A., KURODA, M.J., SCHMITZ, J.E., LETVIN, N.L., CAULFIELD, M.J., BETT, A.J., YOUIL, R., KASLOW, D.C., and EMINI, E.A. (2002). Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331-335.
41. SIEGEL, R.M., CHAN, F.K., CHUN, H.J., and LENARDO, M.J. (2000). The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat. Immunol. 1, 469-474.
42. SONG, W., KONG, H.L., TRAKTMAN, P., and CRYSTAL, R.G. (1997). Cytotoxic T lymphocyte responses to proteins encoded by heterologous transgenes transferred in vivo by adenoviral vectors. Hum. Gene Ther. 8, 1207-1217.
43. + cytotoxic T lymphocytes is dependent on cellular activation and perforin-mediated killing. Eur. J. Immunol. 34, 2459-2470.
44. SULLIVAN, N.J., SANCHEZ, A., ROLLIN, P.E., YANG, Z.Y., and NABEL, G.J. (2000). Development of a preventive vaccine for Ebola virus infection in primates. Nature 408, 605-609.
45. + T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J. Virol. 78, 2666-2673.
46. SURESH, M., WHITMIRE, J.K., HARRINGTON, L.E., LARSEN, C.P., PEARSON, T.C., ALTMAN, J.D., and AHMED, R. (2001). Role of CD28-B7 interactions in generation and maintenance of CD8 T cell memory. J. Immunol. 167, 5565-5573.
47. + T cells. J. Immunol. 165, 5537-5543.
48. THUMMALA, N.R., GHOSH, S.S., LEE, S.W., REDDY, B., DAVIDSON, A., HORWITZ, M.S., CHOWDHURY, J.R., and CHOWDHURY, N.R. (2002). A non-immunogenic adenoviral vector, coexpressing CTLA4Ig and bilirubin-uridine- diphosphoglucuronateglucuronosyltransferase permits long-term, repeatable transgene expression in the Gunn rat model of Crigler-Najjar syndrome. Gene Ther. 9, 981-990.
49. TOES, R.E., OFFRINGA, R., BLOM, R.J., BRANDT, R.M., VAN DER EB, A.J., MELIEF, C.J., and KAST, W.M. (1995). An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene. J. Immunol. 154, 3396-3405.
50. + T cells clear influenza virus by perform or Fas-dependent processes. J. Immunol. 159, 5197-5200.
51. VERMEIREN, I., CEUPPENS, I.L., HAEGEL-KRONENBERGER, H., DE BOER, M., BOON, L., and VAN GOOL, S.W. (2004). Blocking B7 and CD40 co-stimulatory molecules decreases antiviral T cell activity. Clin. Exp. Immunol. 135, 253-258.
52. VIDAL, S., KONO, D.H., and THEOFILOPOULOS, A.N. (1998). Loci predisposing to autoimmunity in MRL-Fas lpr and C57BL/6-Faslpr mice. J. Clin. Invest. 101, 696-702.
53. WALSH, C.M., MATLOUBIAN, M., LIU, C.C., UEDA, R., KURAHARA, C.G., CHRISTENSEN, J.L., HUANG, M.T., YOUNG, J.D., AHMED, R., and CLARK, W.R. (1994). Immune function in mice lacking the perforin gene. Proc. Natl. Acad. Sci. U.S.A. 91, 10854-10858.
54. + T cells do not require costimulation for proliferation and differentiation into cytotoxic effector cells. J. Immunol. 164, 1216-1222.
55. WODARZ, D., and JANSEN, V.A. (2001). The role of T cell help for anti-viral CTL responses. J. Theor. Biol. 211, 419-432.
56. YANG, Y., ERTL, H.C., and WILSON, J.M. (1994a). MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1, 433-442.
57. YANG, Y., NUNES, F.A., BERENCSI, K., FURTH, E.E., GONCZOL, E., and WILSON, J.M. (1994b). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 91, 4407-4411.
58. YANG, Y., XIANG, Z., ERTL, H.C., and WILSON, J.M. (1995). Upregulation of class I major histocompatibility complex antigens by interferon γ is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc. Natl. Acad. Sci. U.S.A. 92, 7257-7261.
59. + CTL directed against herpes simplex virus-infected cells. J. Immunol. 162, 6100-6106.
60. ZHANG, H.G., LIU, D., HEIKE, Y., YANG, P., WANG, Z., WANG, X., CURIEL, D.T., ZHOU, T., and MOUNTZ, J.D. (1998). Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen presenting cells. Nat. Biotechnol. 16, 1045-1049.
61. ZHANG, H.G., XIE, J., XU, L., YANG, P., XU, X., SUN, S., WANG, Y., CURIEL, D.T., HSU, H.C., and MOUNTZ, J.D. (2002). Hepatic DR5 induces apoptosis and limits adenovirus gene therapy product expression in the liver. J. Virol. 76, 5692-5700.